Theravance Biopharma Inc - Company Profile
Powered by 
All the sales intelligence you need on Theravance Biopharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Theravance Biopharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Theravance Biopharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company. It discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Its marketed product, Yupelri (revefenacin), is an inhalation solution, which is approved for the maintenance treatment of COPD. The product is used by patients with COPD who require or prefer nebulized delivery for maintenance therapy. Theravance Biopharma collaborates with Viatris Inc for the commercialization of Yupelri. The company has subsidiaries in the US, Ireland, and the UK. Theravance Biopharma is headquartered in George Town, Cayman Islands.
Headquarters
Cayman Islands
Address
Ugland House, South Church Street, George Town, KY1-1104
Website
www.theravance.com
Telephone
1 345 6508086000
No of Employees
90
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TBPH (NASD)
Revenue (2024)
$107.5M
66.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
287.7%
(2024 vs 2023)
Market Cap*
$877.5M
Net Profit Margin (2024)
XYZ
212.5%
(2024 vs 2023)
* As of and is in US$
Theravance Biopharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Yupelri (revefenacin): | Yupelri |
| Inhalation Solution | Trelegy |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In June, the company signed an agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK for US$225 million. |
| 2025 | Regulatory Approval | In June, the company received approval from China's National Medical Products Administration (NMPA) for Yupelri (revefenacin) inhalation solution for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China. |
| 2023 | Regulatory Approval | In May, the company received Orphan Drug Designation (ODD) status from US Food and Drug Administration (FDA) for ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). |
Competitor Comparison
| Key Parameters | Theravance Biopharma Inc | AstraZeneca Plc | Novartis AG | Sanofi | GSK plc |
|---|---|---|---|---|---|
| Headquarters | Cayman Islands | United Kingdom | Switzerland | France | United Kingdom |
| City | George Town | Cambridge | Basel | Paris | London |
| State/Province | - | Cambridgeshire | Basel-Stadt | Ile-de-France | England |
| No. of Employees | 90 | 96,100 | 75,267 | 76,493 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rick E. Winningham | Chief Executive Officer; Director | Executive Board | 2014 | 66 |
| Susannah Gray | Chairperson | Executive Board | 2024 | 65 |
| Aziz Sawaf | Senior Vice President - Operations Strategy; Chief Financial Officer | Senior Management | 2023 | 44 |
| Stacy Pryce | Chief Strategy Officer; Senior Vice President | Senior Management | 2022 | - |
| Stuart Knight | Chief Information Officer; Senior Vice President - IT&I | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer